The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | Metabolic-only response assessment for the omission of RNRT for Hodgkin lymphoma: the cHOD17 trial
Jamie Flerlage, MD, MS, University of Rochester, Rochester, NY, briefly introduces the Phase II cHOD17 trial (NCT03755804), a study investigating the use of metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL). This approach aims to reduce the incidence of late effects and toxicity in this patient population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’m really excited to share today the results of our trial, cHOD17, that utilizes metabolic-only response assessment to help decide which patients can safely have radiation eliminated. Radiation was the first cure for Hodgkin lymphoma. It works very well, but there are risks and benefits to everything. The goal today is to know who still needs those therapies and who can safely have them eliminated...
I’m really excited to share today the results of our trial, cHOD17, that utilizes metabolic-only response assessment to help decide which patients can safely have radiation eliminated. Radiation was the first cure for Hodgkin lymphoma. It works very well, but there are risks and benefits to everything. The goal today is to know who still needs those therapies and who can safely have them eliminated. What metabolic-only response assessment says is, this fancy scan called a PET scan that utilizes essentially a highlighter to highlight the areas of lymphoma, is very effective at determining which patients after two cycles or two months of treatment no longer need radiation at the end because their disease has responded successfully. So in this era of medicine we’re in, we try to use every piece to treat our patients the best we can, which looks like a treatment plan where radiation is part of it because it works so well, but where it’s eliminated for every patient that can have that late effect and toxicity avoided. And that is what we are showing from cHOD17.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
